United Therapeutics CEO sells $4.76M in stock after option exercise
Covered in this story
Analyst targets on United Therapeutics
- Goldman Sachs: at $472 · target $321 by Sep 2027 · Sell via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $UTHR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on United Therapeutics →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.